Lilly/Novo Get Priority Reviews For Lowering Drug Prices

 
• By Jessica Merrill
  
Lilly and Novo Nordisk gained priority review vouches for lower GLP-1 prices (Shutterstock)

More from Drug Pricing

More from Business